Skip to main content
رجوع
JANX logo

Janux Therapeutics, Inc.

جودة البيانات: 100%
JANX
NASDAQ Healthcare Biotechnology
KWD 13.90
▼ KWD 0.16 (-1.14%)
القيمة السوقية: 845.56M
نطاق اليوم
KWD 13.86 KWD 14.27
نطاق 52 أسبوعًا
KWD 12.12 KWD 35.34
حجم التداول
659,972
متوسط 50 يوم / 200 يوم
KWD 13.73 / KWD 21.21
الإغلاق السابق
KWD 14.06

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -7.4 0.4
P/B 0.9 2.9
ROE % -11.5 3.7
Net Margin % -1136.3 3.8
Rev Growth 5Y % 28.8 10.0
D/E 0.0 0.2

النقاط الرئيسية

Revenue grew 28.77% annually over 5 years — strong growth
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -83.28M
Revenue growth is decelerating — 1Y growth trails 5Y average by 34.32%

النمو

Revenue Growth (5Y)
28.77%
Revenue (1Y)-5.55%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-11.48%
ROIC-12.08%
Net Margin-1136.25%
Op. Margin-1576.67%

الأمان

Debt / Equity
0.02
Current Ratio39.04
Interest Coverage0.00

التقييم

P/E Ratio
-7.44
P/B Ratio0.88
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -5.55% Revenue Growth (3Y) 11.23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 28.77% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10.00M Net Income (TTM) -113.63M
ROE -11.48% ROA -11.34%
Gross Margin 79.71% Operating Margin -1576.67%
Net Margin -1136.25% Free Cash Flow (TTM) -83.28M
ROIC -12.08% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 39.04
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -7.44 P/B Ratio 0.88
P/S Ratio 84.56 PEG Ratio -0.18
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 845.56M Enterprise Value 815.37M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10.00M 10.59M 8.08M 8.61M 3.64M
Net Income -113.63M -68.99M -58.29M -63.06M -32.67M
EPS (Diluted) -1.83 -1.28 -1.32 -1.52 -0.79
Gross Profit 7.97M 8.53M 6.13M 7.77M 3.64M
Operating Income -157.67M -98.85M -72.98M -67.09M -32.93M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.00B 1.06B 380.41M 364.01M 379.82M
Total Liabilities 44.74M 38.74M 36.06M 43.27M 13.50M
Shareholders' Equity 956.82M 1.02B 344.35M 320.74M 366.33M
Total Debt 22.14M 23.03M 24.54M 25.31M 194,000.0
Cash & Equivalents 52.33M 430.61M 19.21M 51.43M 35.58M
Current Assets 975.89M 1.03B 349.24M 332.44M 377.02M
Current Liabilities 25.00M 17.46M 13.03M 16.51M 12.80M